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Anaemia is a common complication of chemotherapy. Since
anaemia can lead to different symptoms, such as fatigue, respi-
ratory distress and chest pain, thereby diminishing physical
capacity and quality of life, it is generally accepted that anaemia
should be corrected. Treatment options include red blood cell
transfusion (RBCT), erythropoietin (EPO) administration or a
combination of both. OBJECTIVE: Our objective was to carry
out a cost-effectiveness analysis of treatment with EPO (ery-
thropoietin alpha) compared to traditional treatment with RBCT
for patients with chemotherapy-induced anaemia in Sweden
from a hospital perspective. METHOD: We developed a model
for Swedish treatment practice (patient characteristics, response
rates, and RBC transfusion data taken from Swedish observa-
tional data), and Swedish unit costs, based on a model commis-
sioned by the National Institute of Clinical Excellence, UK.
Incremental costs associated with EPO treatment compared to
treatment with RBCT, were estimated. Different cancer types and
populations were modelled by varying initial Hb, response and
mortality rates. RESULTS: The model results on costs corre-
spond well to real world data from three big hospitals in Sweden.
Average costs per patient are SEK34,900 for EPO and SEK
12,400 for RBCT. The cost per QALY gained from admini-
stration of EPO assuming a survival beneﬁt attributable to EPO
treatment was estimated at SEK 120,000. The survival beneﬁt
from EPO is debated, and has a major impact of the results.
Excluding this beneﬁt gives an estimated cost of SEK 365,000
per QALY. EPO treatment is most cost-effective in patients with
initial Hb of 9–10 g/dl. The cost-effectiveness-ratio is also 
moderately sensitive to changes in the response rate to EPO,
baseline mortality, the cost of EPO and the estimated QALY gain 
from EPO administration. CONCLUSION: The estimated cost
per QALY falls well within the range acceptable in Sweden. 
The cost-effectiveness of EPO varies between different cancer
populations.
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OBJECTIVES: Organized nationwide screening programme for
cervical cancer was introduced in Hungary in 2003. Women
between the ages 25–65 are invited by a personal letter and a 3
years screening interval has been applied. Before the implemen-
tation of organized screening programme there was an oppor-
tunistic screening. The aim of this study is to analyse the three
year screening rate (attendance or coverage) of the organized
programme according to counties. METHODS: The data derive
from the ﬁnancial database of the National Health Insurance
Fund Administration (OEP) of Hungary covering the period 
of 2000–2005. We calculated the three-year screening rate of 
two periods: 2000–2002 without and 2003–2005 with organized
screening programme for women aged 25–64. Screening is
deﬁned with cytological examination of Papanicolau smear and
includes all smears taken either within or outside of the orga-
nized programme. RESULTS: The age speciﬁc screening rate of
women aged 25–64 years increased from 48, 45% in 2000–2002
without organized screening programme to 52, 65% in
2003–2005 following the introduction of organized screening
programme. There were signiﬁcant differences in the screening
rate (attendance or coverage) among counties with the highest
values in county Baranya (58, 59%), Tolna (55, 35%), Borsod-
Abaúj-Zemplén (54, 61%) and the lowest values in county 
Jász-Nagykun-Szolnok (40, 06%), Vas (41, 47%), Veszprém (42,
52%). From 2000–2002 to 2003–2005 we found the largest
increase in the following counties: Veszprém (14.35 percent
point), Borsod-Abaúj-Zemplén (7.69 percent point), Békés (5.46
percent point). The gap between the counties with the highest
and lowest screening rate decreased. CONCLUSIONS: We
found signiﬁcant differences in the screening rate among coun-
ties, which should be reduced. However, the introduction of
organized cervical screenig programme lead to closing up the
between county differences.
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OBJECTIVES: To develop a simulation model for estimating the
future impact on deaths and new bowel cancer registrations
under alternative bowel cancer screening programme implemen-
tation and design strategies. METHODS: The UK began phasing
in a faecal occult blood test (FOBT) bowel cancer screening pro-
gramme for all persons aged 60–69 in April 2006. We ﬁtted a
novel Bayesian autoregressive age-period-cohort model (Bray
2002) to bowel cancer incidence and mortality data in England
1993–2003/4 (ONS/GAD 2005) that uses parameters efﬁciently
and provides credible intervals for assessing projection uncer-
tainty. We then used the model with results taken from separate
cohort-based bowel cancer natural history modelling (Tappen-
den 2004) and government age- and gender-speciﬁc population
projections to estimate bowel cancer incidence and mortality for
2003–2016 under various bowel cancer screening program
design and implementation strategies. RESULTS: The model ﬁt
the data well. We estimate that phased implementation of the
UK bowel screening program will result in 2440 undetected
cancers (95% CI 808–10,160) and 244 (95% CI 114–610) addi-
tional bowel cancer deaths in 2006–8. Further, a programme
combining FOBT with ﬂexible sigmoidoscopy would detect an
estimated 737 (95% CI 207–3917) more bowel cancers and
prevent 389 (95% CI 156–1168) more deaths than FOBT alone.
CONCLUSIONS: This model provides a valuable tool for 
generating point and interval estimates of the long-term popu-
lation impact of alternative bowel cancer screening program
implementation and design strategies, and can be updated as 
new information arises. Projection uncertainty arises from the
model itself and the disease natural history information used to
inform it.
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OBJECTIVES: To describe factors inﬂuencing inequitable access
to radiation therapy among cancer patients in Thailand by
exploring the current situation and problems of both demand
and supply sides after implementation of the policy on universal
coverage. The study aimed to improve efﬁciency in health
resource allocation and equitable access to expensive health ser-
vices by using radiation therapy as the case study. METHODS:
